KRT88P and colorectal carcinoma: However, univariate and multivariate analyses for the anti-HBc positive CRC patients undergoing curative surgical resection revealed that anti-HBc ≥ 8.8 (HR, 3.510; 95% CI, 1.718–7.17; P = .001) and stage III (HR, 3.038; 95% CI, 1.423–6.484; P = .004) were associated with worse OS; anti-HBc ≥ 8.8 (HR, 5.747; 95% CI, 2.789–11.842; P < 0.001) and stage III (HR, 3.722; 95% CI, 1.752–7.908; P < .001) were associated with worse TTP; only anti-HBc ≥ 8.8 (HR, 3.754; 95% CI, 1.054–13.369; P = .041) was associated with worse HMFS (Table 3).